Jefferies reiterates Altria stock Underperform rating at $60

Jefferies reiterated its Underperform rating on Altria with an unchanged $60 price target, implying downside from the cited $66.95 share price, despite management's premium-brand pricing strategy. Altria reported Q2 2026 adjusted EPS of $1.48, missing the $1.50 consensus by $0.02, while revenue of $6.11B exceeded the $5.35B estimate; cigarette-volume pressures remain a key concern. The company raised its full-year earnings outlook and increased its quarterly dividend 4.7% to $1.11 per share, supporting a 6.63% dividend yield.

Analysis

The actionable signal is not the isolated downgrade but the widening gap between MO’s cash-yield support and its underlying combustible-volume trajectory. Further price realization can protect near-term EPS, but at a point it raises down-trading and illicit-market risk rather than expanding profit pools; that makes the equity increasingly dependent on multiple stability and capital returns rather than organic growth. A sustained deterioration in retail tobacco sell-through would pressure the market’s willingness to capitalize MO at a defensive-staples multiple despite the dividend.

Competitive asymmetry favors PM over MO on a 6-18 month view: PM has a broader smoke-free platform and international growth offsets, whereas MO’s U.S. franchise has less room to trade pricing for volume. BTI is a cheaper alternative for investors seeking tobacco cash flows, although its FX and U.S. regulatory exposure make it a less clean substitute. MO’s key upside catalyst is credible acceleration in reduced-risk product economics; absent disclosed category share, unit economics, and regulatory milestones, that remains a watch item rather than a valuation rerating thesis.

The article’s source quality is a risk in itself: internally inconsistent framing and unverified management attribution reduce confidence that the cited meeting adds incremental information. Do not trade the headline reaction. Over the next 1-3 months, watch scanner-data volume trends, promotional intensity, and management’s ability to sustain EPS guidance without incremental pricing; over 6-18 months, FDA actions and reduced-risk execution determine whether the yield is a floor or compensation for secular erosion.

Key Decisions for Investors

• Maintain/establish a 3-6 month relative short MO / long PM position, sized beta-neutral: PM offers a more credible growth offset while MO remains more exposed to U.S. combustible elasticity. Target 8-12% relative return; cover if MO reiterates or raises EPS guidance while premium-combustible volumes stabilize for two consecutive reported periods.
• For income mandates, do not add MO solely on yield. Enter only after verifying next-quarter cigarette shipment/retail-volume trends and reduced-risk segment contribution; require a valuation discount versus PM that compensates for a 2-3% annual volume-decline scenario.
• Use MO downside puts or put spreads around the next earnings event only if retail scanner data worsen materially before the print. The catalyst is a guidance cut driven by volume and/or promotional spending; avoid outright long-volatility if implied volatility already prices a large post-earnings move.
• Monitor FDA reduced-risk authorization, NJOY share/profitability disclosures, and U.S. tobacco category scanner data as thesis pivots. A favorable regulatory development or evidence that non-combustible profits can offset combustible declines would invalidate the relative-short thesis.